Clinical Trials Using Anti-EGFR Fluorescence Imaging Agent ABY-029

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-EGFR Fluorescence Imaging Agent ABY-029. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • ABY-029 for the Imaging of Operable Head and Neck Cancer prior to Surgery

    This early phase I trial studies how well ABY-029 works for the imaging head and neck cancer prior to surgery. ABY-029 is an experimental drug that may light up portions of many tumors. This trial aims to measure the amount of ABY-029 that reaches the head and neck cancer with the help of imaging devices. This information may help to guide future head and neck surgery.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • ABY-029 in Imaging Participants with Recurrent Glioma

    This pilot early phase I trial studies how well anti-EGFR fluorescence imaging agent ABY-029 (ABY-029) works in imaging participants with glioma that has come back. ABY-029 is taken up by brain tumors and detected using an imaging system. This may help surgeons remove as much of the tumor as possible safely.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • ABY-029 in Identifying Tumor Tissue in Patients with Sarcoma Undergoing Surgery

    This early phase I trial studies whether ABY-029, an anti-EGFR fluorescence imaging agent, can be seen in patients with sarcoma undergoing surgery. ABY-029 can light up portions of many tumors, making them glow a green color. This study is being done to see if ABY-029 can be detected in patients with sarcoma.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire